JP2021526123A - オートタキシン阻害剤とその使用 - Google Patents

オートタキシン阻害剤とその使用 Download PDF

Info

Publication number
JP2021526123A
JP2021526123A JP2020540731A JP2020540731A JP2021526123A JP 2021526123 A JP2021526123 A JP 2021526123A JP 2020540731 A JP2020540731 A JP 2020540731A JP 2020540731 A JP2020540731 A JP 2020540731A JP 2021526123 A JP2021526123 A JP 2021526123A
Authority
JP
Japan
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
pharmaceutically acceptable
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526123A5 (cg-RX-API-DMAC7.html
Inventor
ジン,ボハン
ドン,シン
ハン,ジーン
リー,ヤオ
Original Assignee
シーチュアン ハイスコ ファーマシューティカル シーオー.,エルティーディー.
シーチュアン ハイスコ ファーマシューティカル シーオー.,エルティーディー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーチュアン ハイスコ ファーマシューティカル シーオー.,エルティーディー., シーチュアン ハイスコ ファーマシューティカル シーオー.,エルティーディー. filed Critical シーチュアン ハイスコ ファーマシューティカル シーオー.,エルティーディー.
Publication of JP2021526123A publication Critical patent/JP2021526123A/ja
Publication of JP2021526123A5 publication Critical patent/JP2021526123A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020540731A 2018-05-29 2019-05-29 オートタキシン阻害剤とその使用 Pending JP2021526123A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677459P 2018-05-29 2018-05-29
US62/677,459 2018-05-29
US201862731003P 2018-09-13 2018-09-13
US62/731,003 2018-09-13
PCT/CN2019/089025 WO2019228403A1 (en) 2018-05-29 2019-05-29 Autotaxin inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2021526123A true JP2021526123A (ja) 2021-09-30
JP2021526123A5 JP2021526123A5 (cg-RX-API-DMAC7.html) 2022-05-27

Family

ID=68697812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020540731A Pending JP2021526123A (ja) 2018-05-29 2019-05-29 オートタキシン阻害剤とその使用

Country Status (6)

Country Link
US (2) US10711000B2 (cg-RX-API-DMAC7.html)
EP (1) EP3728257A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021526123A (cg-RX-API-DMAC7.html)
CN (1) CN111801328B (cg-RX-API-DMAC7.html)
CA (1) CA3089527A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019228403A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021513551A (ja) * 2018-02-14 2021-05-27 スーチョウ、シノベント、ファーマスーティカルズ、カンパニー、リミテッドSuzhou Sinovent Pharmaceuticals Co., Ltd. 複素環式化合物、その応用及びそれを含有する医薬組成物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019228403A1 (en) 2018-05-29 2019-12-05 Fronthera U.S. Pharmaceuticals Llc Autotaxin inhibitors and uses thereof
CN111393459B (zh) * 2020-04-16 2022-07-22 南京安纳康生物科技有限公司 Shp2抑制剂及其用途
JP2023533294A (ja) * 2020-07-09 2023-08-02 スージョウ アーク バイオファーマシューティカル カンパニー リミテッド Atx阻害剤及びその製造方法並びに使用
CN113912600A (zh) * 2020-07-09 2022-01-11 苏州爱科百发生物医药技术有限公司 一种atx抑制剂及其制备方法和应用
WO2022026922A2 (en) * 2020-07-31 2022-02-03 Genentech, Inc. Methods for treating exacerbations of inflammatory respiratory diseases
CN114315825A (zh) * 2020-09-30 2022-04-12 江西济民可信集团有限公司 吡啶并咪唑衍生物及其制备方法和应用
WO2022074459A2 (en) * 2020-10-06 2022-04-14 Ildong Pharmaceutical Co., Ltd. Autotaxin inhibitor compounds
EP4242208A4 (en) * 2020-11-04 2025-01-15 Xizang Haisco Pharmaceutical Co., Ltd. DEUTERATED DERIVATIVE USED AS ATX INHIBITOR, AND ITS APPLICATION
CN112675308B (zh) * 2020-12-09 2023-05-05 中国人民解放军军事科学院军事医学研究院 抑制enpp2基因和/或蛋白表达的物质在制备治疗多发性骨髓瘤的药物中的应用
FI4274572T3 (fi) 2021-01-05 2026-03-27 Zydus Lifesciences Ltd Uusia autotaksiinin inhibiittoreita
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
TW202342138A (zh) * 2022-03-31 2023-11-01 大陸商蘇州愛科百發生物醫藥技術有限公司 Atx抑制劑或其鹽的結晶形式及其制備方法與應用
WO2023211684A2 (en) * 2022-04-29 2023-11-02 Noetix Pharma Llc Prevention and treatment of post-operative cognitive dysfunction (pocd)
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139882A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2014202458A1 (en) * 2013-06-19 2014-12-24 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019158107A1 (zh) * 2018-02-14 2019-08-22 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201908293A (zh) * 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
JP7274767B2 (ja) 2018-05-24 2023-05-17 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 芳香族複素環式化合物及びその医薬組成物
WO2019228403A1 (en) 2018-05-29 2019-12-05 Fronthera U.S. Pharmaceuticals Llc Autotaxin inhibitors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139882A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2014202458A1 (en) * 2013-06-19 2014-12-24 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2019158107A1 (zh) * 2018-02-14 2019-08-22 苏州信诺维医药科技有限公司 一种杂环化合物、其应用及含其的药物组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, JPN6023025388, 1 May 2017 (2017-05-01), pages 3580 - 3590, ISSN: 0005086903 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, JPN6023025389, 18 August 2017 (2017-08-18), pages 7371 - 7392, ISSN: 0005086902 *
野崎 正勝 他, 創薬化学, vol. 第1版, JPN7023001664, 1995, JP, pages 98 - 99, ISSN: 0005086904 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021513551A (ja) * 2018-02-14 2021-05-27 スーチョウ、シノベント、ファーマスーティカルズ、カンパニー、リミテッドSuzhou Sinovent Pharmaceuticals Co., Ltd. 複素環式化合物、その応用及びそれを含有する医薬組成物

Also Published As

Publication number Publication date
EP3728257A4 (en) 2021-06-23
US10711000B2 (en) 2020-07-14
US20190367515A1 (en) 2019-12-05
CA3089527A1 (en) 2019-12-05
CN111801328B (zh) 2023-06-02
EP3728257A1 (en) 2020-10-28
WO2019228403A1 (en) 2019-12-05
US11040972B2 (en) 2021-06-22
CN111801328A (zh) 2020-10-20
US20200354357A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
CN111801328B (zh) 自分泌运动因子抑制剂及其用途
AU2020343671B2 (en) RIP1 inhibitory compounds and methods for making and using the same
EP3692040B1 (en) Chemical compounds
AU2018332501B2 (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
KR20250172881A (ko) 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도
JP6204985B2 (ja) RORγT阻害剤としての3−アミノシクロアルキル化合物およびその使用
JP6402179B2 (ja) 新規な、NIK阻害剤としての1−(4−ピリミジニル)−1H−ピロロ[3,2−c]ピリジン誘導体
JP2022505987A (ja) Tyk2阻害剤およびその使用
US20240246932A1 (en) Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
EP3766882B1 (en) Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof
MX2015001941A (es) Compuestos de ácido benzoico 4-heteroarilo-sustituido como inhibidores de rorgammat y sus usos.
WO2007055418A1 (ja) アザ置換スピロ誘導体
EA007063B1 (ru) ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β;
CA2957898C (en) Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
EA023574B1 (ru) ПРОИЗВОДНЫЕ 6-ЦИКЛОБУТИЛ-1,5-ДИГИДРОПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE9A
US20200071326A1 (en) Tam kinase inhibitors
CN105085482B (zh) 取代的哌嗪化合物及其使用方法和用途
US20250235510A1 (en) Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist peptides
JP2022525948A (ja) 高血糖症の治療に有用なヘテロアリール(ヘテロシクリル)メタノール化合物
WO2016088813A1 (ja) 新規ジアザビシクロ[2.2.2]オクタン誘導体
JP2022525795A (ja) 高血糖症の治療に有用なヘテロシクロリル(フェニル)メタノール化合物
JP2024529508A (ja) ピロロ[2,3-b]ピリジンPGDH阻害剤、および製造方法ならびに使用方法
US20260055057A1 (en) Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078674A1 (en) Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
RU2775505C2 (ru) Изохинолин-3-иловые карбоксамиды и их получение и применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201029

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210629

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20220425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231212